Evidence map›Paper›PMID 38518539›Full record

Observational studyThe journal of nutrition, health & aging2024

Prognostic impact of neurocognitive disorders in older patients with cancer: the ELCAPA prospective cohort study.

Catherine Conti, Elena Paillaud, Marie Laurent, Johanne Poisson, Pascaline Boudou-Rouquette, Maxime Frelaut, Pierre Gay, Johanna Canovas, Philippe Caillet, Soraya Mebarki and 2 more

Open access · goldAbstract readObservational StudyMulticenter Study
In one paragraph

Observational study in The journal of nutrition, health & aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Catherine ContiAP-HP, Paris Cancer Institute CARPEM, Hôpital Européen Georges Pompidou, Department of Geriatrics, F-75015 Paris, France; Université Paris-Est, Inserm, 7376- IMRB, F-94000 Créteil, France. Electronic address: catherine.conti@aphp.fr.
Elena PaillaudAP-HP, Paris Cancer Institute CARPEM, Hôpital Européen Georges Pompidou, Department of Geriatrics, F-75015 Paris, France; Université Paris-Est, Inserm, 7376- IMRB, F-94000 Créteil, France.
Marie LaurentUniversité Paris-Est, Inserm, 7376- IMRB, F-94000 Créteil, France; AP-HP, Hopital Henri-Mondor, Department of Internal Medicine and Geriatrics, F-94010 Creteil, France.
Johanne PoissonAP-HP, Paris Cancer Institute CARPEM, Hôpital Européen Georges Pompidou, Department of Geriatrics, F-75015 Paris, France; Université Paris-Cité, Center for Research on Inflammation, Inserm U1149, F-75018 Paris, France.
Pascaline Boudou-RouquetteAP-HP, Hôpital Cochin - Port-Royal, Department of Oncology, F-75014 Paris, France.
Maxime FrelautGustave Roussy Cancer Campus, F-94076 Villejuif, France.
Pierre GayAP-HP, Paris Cancer Institute CARPEM, Hôpital Européen Georges Pompidou, Department of Geriatrics, F-75015 Paris, France.
Johanna CanovasAP-HP, Paris Cancer Institute CARPEM, Hôpital Européen Georges Pompidou, Department of Geriatrics, F-75015 Paris, France.
Philippe CailletAP-HP, Paris Cancer Institute CARPEM, Hôpital Européen Georges Pompidou, Department of Geriatrics, F-75015 Paris, France; Université Paris-Est, Inserm, 7376- IMRB, F-94000 Créteil, France.
Soraya MebarkiAP-HP, Paris Cancer Institute CARPEM, Hôpital Européen Georges Pompidou, Department of Geriatrics, F-75015 Paris, France.
Amaury BroussierUniversité Paris-Est, Inserm, 7376- IMRB, F-94000 Créteil, France; AP-HP, Hôpitaux Henri-Mondor/Emile Roux, Department of Geriatrics, F-94456 Limeil-Brevannes, F-94000 Créteil, France.
Florence Canouï-PoitrineUniversité Paris-Est, Inserm, 7376- IMRB, F-94000 Créteil, France; AP-HP, Hopital Henri-Mondor, Public Health Departement, F-94010 Creteil, France.
Inserm · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Cochin · FRInstitut Gustave Roussy · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the prognostic value of neurocognitive disorder (NCD) for 12 month-overall mortality in patients aged 70 or more with a solid cancer.

designprospective, observational, multicenter cohort. SETTING AND

participantsWe analyzed data from the ELCAPA longitudinal multicenter observational cohort of patients aged 70 or over, referred for a geriatric assessment (GA) before a new cancer treatment modality between January 31st, 2007, and December 29th, 2017. We defined the baseline NCD in four classes: no NCD, mild NCD, moderate NCD, and major NCD, based on the Mini-Mental State Examination (MMSE) score, memory complaint, and the Instrumental Activities of Daily Living (IADL) score. STATISTICAL

methodsWe compared the baseline characteristics of patients according to NCD classes, globally and by pairs (with Bonferroni' correction). Prognosis value of NCD classes were analysed by using univariable and then multivariable 12 month survival analysis with age as time-variable and with and without adjustement for the treatment strategy (curative, palliative or exclusive supportive care).

results2784 patients with solid-cancer were included, with a median [interquartile range] age of 82 [78;86]. 36% of the patients were free of NCD, 34% had a mild NCD, 17% had a moderate NCD, and 13% had a major NCD. We identified the following independent prognostic factors for 12 month-overall mortality: NCD (adjusted hazard ratio (aHR) [95% confidence interval (CI)] for a major NCD = 1.54 [1.19-1.98] (p < 0.001), type of cancer, metastatic status, inpatient consultation, poor general health (assessed as the level of fatigue and Eastern Cooperative Oncology Group performance status [ECOG-PS]), greater weight loss, palliative treatment, and exclusive supportive care. Additional adjustment for the treatment strategy did not greatly change the strength of the association of a major NCD with 12 month-overall mortality (HR [95%CI] = 1.78 [1.39-2.29] (p < 0.001).

conclusionOur results suggest that the presence of a major NCD has direct prognostic value (independently of other geriatric factors, the type of cancer and the treatment strategy) in older patients with a solid cancer.

Indexed as

Geriatric AssessmentNeoplasmsNeurocognitive DisordersActivities of Daily LivingAgedAged, 80 and overFemaleHumansLongitudinal StudiesMalePrognosisProspective StudiesCancerMortalityNeurocognitive disorderOlder adultPrognostic value

Identifiers

PMID38518539
PMCPMC12877268
OpenAlexW4393031694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.